[O32-1] SUNFISH: 48-months efficacy and safety of risdiplam in types 2 and 3 spinal muscular atrophy
○Kayoko Saito1, Tamaki Kato1, John W Day2, Nicolas Deconinck3, Elena S Mazzone4, Andres Nascimento5, Maryam Oskoui6, Carole Vuillerot7, Giovanni Baranello8, Laurent Servais9, Jessica Braid10, Marianne Gerber10, Carmen Martin10, Wai Yin Yeung10, Eugenio Mercuri4 (1.Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan, 2.Department of Neurology, Stanford University, Palo Alto, CA, USA, 3.Neuromuscular Reference Center, UZ Gent, Ghent, Belgium, 4.Pediatric Neurology Institute, Catholic University and Nemo Pediatrico, Fondazione Policlinico Gemelli IRCCS, Rome, Italy, 5.Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Deu, Fundacion Sant Joan de Deu, CIBERER - ISC III, Barcelona, Spain, 6.Departments of Pediatrics and Neurology Neurosurgery, McGill University, Montreal, Canada, 7.Department of Pediatric Physical Medicine and Rehabilitation, Hopital Mere Enfant, CHU-Lyon, Bron, France, 8.Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health University College London, London, UK, 9.MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford, Oxford, United Kingdom, 10.F. Hoffmann-La Roche Ltd., Basel, Switzerland)